Jinshan Shen

Kathleen Soucek1
Xiaoli You1
1Kathleen Soucek
1Xiaoli You
Learn More
BACKGROUND AND OBJECTIVES Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept. METHODS The pharmacokinetics, pharmacodynamics (CD86(More)
  • 1